A study to evaluate the potential benefit of the addition of buparlisib to standard therapy (carboplatin and paclitaxel) in the treatment of lung cancer

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 220

Inclusion Criteria

-Patient has histologically and/or cytologically confirmed diagnosis of squamous NSCLC. Diagnosis of mixed histology with a squamous component will be acceptable for enrollment.
- Patient has archival or new tumor tissue for the analysis of PI3K related biomarkers.
- Tumor is Stage IV at the time of signed informed consent (UICC/AJCC version 7)
-Patient has measurable or non-measurable disease according to
RECIST v1.1 criteria (for the Phase II portion, the patient must have measurable disease according to RECIST 1.1 criteria)
- Patient has an Eastern Cooperative Oncology
Group (ECOG) performance status = 1 that the investigator
believes is stable at the time of screening
- Patient has adequate bone marrow and organ function
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Patient has received any prior systemic therapies for metastatic NSCLC. Study treatment in this clinical trial must be the patient’s first systemic treatment for metastatic NSCLC. Patients are eligible if they received neo-adjuvant or adjuvant systemic therapy followed by a disease-free interval exceeding 12 months.
- Patient has symptomatic CNS metastases [patients with asymptomatic CNS metastases may participate in this trial. The patient must have completed any prior local treatment for CNS
metastases = 28 days prior to the start of study treatment
(including radiotherapy and/or surgery, or =14 days for
stereotactic radiosurgery)].
- Patient is currently receiving warfarin or other coumadin derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.
- Patient is currently receiving treatment with drugs known to be strong inhibitors or inducers of isoenzyme CYP3A. The patient must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the treatment is initiated. Switching to a different medication prior to
randomization is allowed.
- Patient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others) or patients with active severe personality disorders (defined according to DSM- IV) are not eligible. Note: for patients
with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug
- Patient has = CTCAE grade 3 anxiety
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL) -Patient who does not apply highly effective
contraception during the study and through the duration as
defined below after the final dose of study treatment.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials